language
Language
Englishchevron_right
attach_money
Currency
$USDchevron_right
dark_mode
Dark Mode
policy
Privacy Policy
gavel
Terms of Service
BSXBSX

$76.85

+1.10
arrow_drop_up1.45%
Market closed·update27 Feb 2026 21:00

$76.8

-0.05
arrow_drop_down0.07%
Post-market·update28 Feb 2026 00:59
Day's Range
75.27-76.84
52-week Range
72.69-109.5

Chart

Loading chart...

Performance

Key Stats

Next Earnings Date2026-02-04
Next Earnings TimeBefore Market Open
Volume21.47M
Average Volume 30d14.22M

AI BSX Summary

Powered by LiveAI
💰
63.22
Valuation (P/E Ratio)
Higher than industry average, indicating potential growth expectations.
📈
0.055
EPS Growth (YoY)
Based on TTM EPS of $1.68 and previous year's EPS (assuming a proportional calculation from quarterly data).
Show More 🔒

AI Scoreboard

Powered by LiveAI
🔒

Overall Analysis

Buy
76

Boston Scientific exhibits strong fundamental performance and benefits from positive thematic trends in healthcare technology. Technical indicators show some mixed signals, suggesting a 'Buy' rating with a watchful approach to short-term price movements.

Strong

Thematic

79

Boston Scientific is well-positioned in several key thematic areas, including medical device innovation, aging populations, and advancements in minimally invasive procedures.

Strong

Fundamental

82

Boston Scientific demonstrates solid financial health, with consistent revenue growth, healthy profitability, and a manageable debt level. Strong free cash flow generation supports its operations and potential for future investment.

Neutral to Bullish

Technical

72

The stock is in a generally bullish trend, trading above key moving averages. However, some oscillators are approaching overbought territory, suggesting potential for short-term consolidation.

FactorScore
Healthcare Innovation & Technology90
Aging Population85
Minimally Invasive Procedures88
Emerging Markets Growth70
Regulatory Landscape65
FactorScore
Valuation65
Profitability80
Growth88
Balance Sheet Health85
Cash Flow82
FactorScore
Trend Analysis85
Momentum70
Volume Confirmation75
Support & Resistance60

AI Investing Checklist

Powered by LiveAI
thumb_up

Bullish Points (7)

Earnings Performance chevron_right

Consistent EPS Beats

The company has exceeded earnings per share (EPS) estimates for the last 8 consecutive quarters, with an average surprise of +7.57%, indicating robust operational execution and forecasting accuracy.

Valuation chevron_right

Favorable P/E to Growth Ratio

The Price-to-Earnings (P/E) ratio of 63.22 is high, but the company's projected earnings growth suggests a Price/Earnings to Growth (PEG) ratio that may be attractive if growth materializes.

Show More 🔒
thumb_down

Bearish Points (7)

Valuation Risk chevron_right

High Trailing P/E Ratio

The trailing P/E ratio of 63.22 is significantly higher than the average of many mature companies, indicating that the stock may be trading at a premium and is sensitive to future earnings performance.

Growth Deceleration chevron_right

Slowing Quarterly Revenue Growth

Quarterly revenue growth has shown variability, with Q1 2025 at 14.5% and Q4 2024 at 12.4%, following a more substantial 2024 annual growth, which might suggest a deceleration in top-line expansion.

Show More 🔒

Calendar

July 2025

23

Next Earnings Date

EPS Est.
Revenue Est.

H: $0.75

A: $0.71

L: $0.70

H: 5.07B

A: 4.96B

L: 4.80B

Profile

Employees (FY)53K
ISIN-
FIGI-

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates in two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat a range of gastrointestinal conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes, as well as endoluminal surgery and infection prevention portfolios; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, urinary and bowel dysfunction, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, penile implants, artificial urinary sphincter, laser system, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator systems, proprietary programming software, radiofrequency ablation, indirect decompression systems, and intraosseous nerve ablation and deep brain stimulation systems. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a left atrial appendage closure (LAAC) device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat, and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.

Seasonals

2025
2024
2023
2022
2021

Price Target

123.03 USD

The 39 analysts offering 1 year price forecasts for BSX have a max estimate of 140.00 and a min estimate of 98.34.

Debt Level and Coverage

Debt
Free cash flow
Cash & equivalents

Financial Position Analysis

Assets
Liabilities

Ownership

Free Float shares
1.48B (99.72%)
Closely held shares
4.21M (0.28%)
1.48B
Free Float shares
1.48B (99.72%)
Closely held shares
4.21M (0.28%)

Capital Structure

Market cap
157.13B
Debt
11.15B
Minority interest
0.00
Cash & equivalents
414M
Enterprise value
167.87B

Valuation - Summary

Market Cap
157B
Net income
1.71B(1.09%)
Revenue
13.4B(8.55%)
157B
Market Cap
157B
Net income
1.71B(1.09%)
Revenue
13.4B(8.55%)
Price to earning ratio (P/E)92.00x
Price to sales ratio (P/S)11.70x

Valuation - Ratios

P/E
P/S

Revenue to Profit Conversion

Revenue
16.75B
COGS
5.26B
Gross Profit
11.49B
OpEx
8.49B
Operating Income
3B
Other & Taxes
1.15B
Net Income
1.85B

Balance Sheet

Total assets
Total liabilities
Liabilities to assets %

Income Statement

Revenue
Net Income
Net Margin

Cash Flow

Operating Cash Flow
Investing Cash Flow
Financing Cash Flow
Show More 🔒